Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been recognized as a Leader in the IDC MarketScape for Worldwide Life Science R&D BPO Services 2018.1
The report credits TCS' leadership to strong discovery research, clinical data management, and pharmacovigilance BPO services. Among other strengths, the report cites TCS' innovation offering, the Advanced Drug Development platform, which provides BPaaS solutions based on cognitive computing, artificial intelligence (AI), and robotics automation.
"In a Business 4.0 world, life sciences companies are embracing digital technologies to drive faster clinical innovation, increase the returns from their R&D investments and meet the demands of an ever changing regulatory landscape," said Debashis Ghosh, President - Life Sciences and Healthcare at TCS. "This recognition by /DC is a reflection of TCS' deep understanding of the life sciences value chain and ability to align our strategy and offerings with our customers' current and future needs."
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. The company offers a full set of services spanning consulting, cognitive business operations and digital transformation services, as well as platform solutions in the life sciences sector.
TCS' robust solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation and cloud to fully digitize the drug development process. TCS' genomics and translational research offerings deliver differentiated value to life sciences companies by combining bioinformatics analysis and DNA sequencing lab capabilities for emerging genomics-driven R&D initiatives.
"While a variety of new business models are being considered and evaluated, companies are concurrently looking to better exploit both technological innovation and best practices from outside of the industry. With a focus on technology, it is clear that this paradigm shift has been long in the making. TCS' Business 4.0 thought leadership framework, strong technical focus and broad service offerings make it a preferred partner to address customers' R&D BPO needs," said Alan S. Louie, Research Director, IDC Health Insights Life Science R&D Strategies and Technology.
"Our deep industry expertise, contextual knowledge, digital technology expertise and advanced platform solutions enable enhanced patient centricity, drive better insights and improve productivity across the R&D value chain, resulting in higher business value for our customers," added Debashis Ghosh.
Shares of TATA CONSULTANCY SERVICES LTD. was last trading in BSE at Rs.1981.45 as compared to the previous close of Rs. 1997.3. The total number of shares traded during the day was 83227 in over 4013 trades.
The stock hit an intraday high of Rs. 2009.95 and intraday low of 1970.55. The net turnover during the day was Rs. 165196142.